Galectin-3 and the Mineralocorticoid Receptor Antagonist Canrenone in Mild Heart Failure

Francesco Clemenza; Serge Masson; Pier Giulio Conaldi; Daniele Di Carlo; Alessandro Boccanelli; Gian Francesco Mureddu; Lucio Gonzini; Donata Lucci; Aldo P. Maggioni; Andrea Di Lenarda; Enrico B. Nicolis; Massimo Vanasia; Roberto Latini; on behalf of the AREA IN-CHF Investigators

doi:10.1253/circj.CJ-17-0656

Rapid Communications

Galectin-3 and the Mineralocorticoid Receptor Antagonist Canrenone in Mild Heart Failure

Francesco Clemenza, Serge Masson, Pier Giulio Conaldi, Daniele Di Carlo, Alessandro Boccanelli, Gian Francesco Mureddu, Lucio Gonzini, Donata Lucci, Aldo P. Maggioni, Andrea Di Lenarda, Enrico B. Nicolis, Massimo Vanasia, Roberto Latini, on behalf of the AREA IN-CHF Investigators

Author information

Francesco Clemenza
Heart Failure Unit, ISMETT
Serge Masson
Department of Cardiovascular Research, IRCCS-Istituto di Ricerche Farmacologiche “Mario Negri”
Pier Giulio Conaldi
Department of Laboratory Medicine and Advanced Biotechnologies, ISMETT
Daniele Di Carlo
Department of Laboratory Medicine and Advanced Biotechnologies, ISMETT
Alessandro Boccanelli
Cardiology Department, Quisisana Hospital
Gian Francesco Mureddu
Cardiology Unit, San Giovanni-Addolorata Hospital
Lucio Gonzini
ANMCO Research Center
Donata Lucci
ANMCO Research Center
Aldo P. Maggioni
ANMCO Research Center
Andrea Di Lenarda
Cardiovascular Center, ASUI
Enrico B. Nicolis
Department of Cardiovascular Research, IRCCS-Istituto di Ricerche Farmacologiche “Mario Negri”
Massimo Vanasia
Therabel GiEnne Pharma
Roberto Latini
Department of Cardiovascular Research, IRCCS-Istituto di Ricerche Farmacologiche “Mario Negri”
on behalf of the AREA IN-CHF Investigators

Keywords: B-type natriuretic peptide, Clinical trials, Galectin-3, Heart failure, Mineralocorticoid receptor antagonist

JOURNAL FREE ACCESS FULL-TEXT HTML

2017 Volume 81 Issue 10 Pages 1543-1546

DOI https://doi.org/10.1253/circj.CJ-17-0656

Browse “Advance online publication” version

Details

Abstract

Background:Galectin-3 (Gal-3) is involved in collagen deposition and inflammation and is a prognostic biomarker in heart failure (HF).

Methods and Results:Gal-3 and other markers of fibrosis or cardiac stress were measured serially in 413 patients with mild HF randomized to the mineralocorticoid receptor antagonist canrenone or placebo to evaluate treatment effect and association with clinical outcome. Gal-3 increased slightly over 6 months in both arms of the study and was associated with clinical endpoints.

Conclusions:Although Gal-3 showed prognostic value, the effect of canrenone on clinical outcomes was unaffected by baseline concentrations of biomarkers of fibrosis or cardiac stress.

Corresponding author

Register with J-STAGE for free!